6505--Budesonide/Formoterol INH

The Department of Veterans Affairs National Acquisition Center is soliciting offers for Budesonide/Formoterol oral inhalers in two strengths: 160mcg/4.5mcg per spray and 80mcg/4.5mcg per spray, each in 10.2-gram canisters. This unrestricted solicitation seeks a single award covering both line items across a base year plus four one-year option periods. Key contract requirements include FDA approval with acceptable current Good Manufacturing Practices status, unique 11-digit NDC numbers specific to the offeror, compliance with bar coding and Drug Supply Chain Security Act requirements, and specified packaging compatibility standards. Non-small business concerns must submit an approved subcontracting plan for contracts valued over $900,000. The proposal due date is May 7, 2026, at 2:30 PM CT, and offerors must submit prices for all line items across the base year and all four option years with a mandatory 0.5% Cost Recovery Fee included in their pricing.

This solicitation does not include a set-aside designation and will result in one aggregate award for both strengths of the inhaler. Base year quantities are 722,021 canisters for the 160mcg/4.5mcg strength and 220,295 canisters for the 80mcg/4.5mcg strength. The products will be distributed through Government Prime Vendor programs serving the Department of Veterans Affairs, Department of Defense, Indian Health Service, Bureau of Prisons, Captain James A. Lovell Federal Health Care Center, and participating State Veterans Homes. Contractors must establish and maintain business-to-business agreements with PPV distributors during a maximum 60-calendar-day implementation period before the ordering period begins. Quarterly sales reports and Cost Recovery Fees are required within 30 calendar days of each quarter's end, and offerors must maintain current SAM registration with Letters of Commitment from manufacturers if they are distributors.